Navigation Links
Atrium Innovations Announces Commencement of a First Normal Course Issuer Bid

QUEBEC CITY, Nov. 10 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX: ATB) announced today that it has filed with the Toronto Stock Exchange ("TSX"), and the TSX has accepted, a Notice of Intention to make a Normal Course Issuer Bid. Under its normal course issuer bid, Atrium intends to purchase up to 1,639,617 of its common shares, representing approximately 5% of the 32,792,340 common shares issued and outstanding as of October 31, 2010. The average daily trading volume for the 6-month period preceding October 31, 2010 represents 83,018 common shares. In accordance with the TSX requirements, a maximum daily purchase of the greater of 25% of this average or 1,000 shares may be made, which represents a total of 20,754 common shares.

Purchases will be made on the open market by Atrium through the facilities of the TSX. The purchases may commence on November 15, 2010 and will terminate on November 14, 2011, or on such earlier date as Atrium will have completed its purchases pursuant to the Notice of Intention to make a Normal Course Issuer Bid filed with the TSX. Atrium will cancel any common shares purchased pursuant to the normal course issuer bid. Atrium will pay the market price of common shares on the TSX at the time of purchase and no purchases of common shares will be made other than open-market purchases.

The Company considers that repurchasing common shares is a sound business and financial decision as shares in circulation will be reduced and the proportionate interest of all remaining shareholders in the share capital of the Company will be increased on a pro rata basis.

No appraisal or valuation regarding the Company, its material assets or securities was prepared within the two years preceding the date of the Notice of Intention to make a Normal Course Issuer Bid.

About Atrium

Atrium Innovations Inc. is a globally recognized leader in the innovation, formulation, production and commercialization of science-based and professionally endorsed dietary supplements for the health & nutrition industry. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 925 employees and operates seven manufacturing facilities. Additional information about Atrium is available on its website at

Cautionary Note and Forward-Looking Statements

This press release is not an offer of securities for sale. This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Atrium Innovations Announces Third Quarter Financial Results of 2010
2. Nucletron Spotlights Innovations During ESTRO29
3. Marrone Bio Innovations to Present Invasive Mussel Control Solution
4. DuPont Leader: Global Demand for Renewable Innovations Growing
5. Stem Cell Innovations to Provide Research and Assay Services to Agennix.
6. Marrone Bio Innovations Announces Two New Executive Appointments
7. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
8. The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009
9. Marrone Bio Innovations Named an IC20 Company
10. Glycos Biotechnologies, Inc. Selected to Present at Alternative Energy Innovations 2009
11. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 27, 2009 to Discuss Third Quarter 2009 Results
Post Your Comments:
(Date:10/13/2015)... October 13, 2015 ARRY ), ... (NASDAQ: JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: ... Life Sciences Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: ... PGNX ) --> Cooperative research and development ... can potentially lead to advancements in the treatment of ...
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson ... clinical data solutions business. , Jeff Parr has spent the past decade providing quality ... Dennison, Thermo Fisher, and Ab Sciex to name a few. He is based ...
(Date:10/13/2015)... the United States , Canada ... 14% of all new cases of kidney cancer.   --> ... and Europe .  PRCC represents about 14% ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison ... ("AstraZeneca") have completed enrolment in a global Phase II study of ...
Breaking Biology Technology:
(Date:10/7/2015)... -- --> --> According ... third quarter 2015 amounted to around 960 MSEK. This exceeds ... was communicated 20 August 2015. --> ... a continued growing demand for the company,s products, the revenues ... than during the third quarter. The revenue guidance for 2015 ...
(Date:10/6/2015)... 2015  Maverix Biomics, Inc., a leading genomic ... software portfolio with the debut of its RNA-Seq ... in eukaryotes. The software is integrated into the ... analysis solution that leverages proven open-source algorithms and ... efforts. Garry Nolan,s laboratory at ...
(Date:10/1/2015)... , Oct. 1, 2015  Biometrics includes diverse ... human body characteristics, such as fingerprints, eye retinas, ... Adoption of biometrics technology has been constantly increasing ... last five years. In addition to the most ... fingerprint recognition, other means of biometric authentication are ...
Breaking Biology News(10 mins):